Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bret Lashner

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Gastroenterology|January 13, 2010
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitisWilliam J Sandborn, Joshua Korzenik, Bret Lashner, et al.
Gastroenterology|March 8, 2008
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trialJames D Lewis, Gary R Lichtenstein, Julius J Deren, et al.
Journal of Crohn'S & Colitis|June 15, 2022
Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrenceSalam P Bachour, Ravi S Shah, Florian Rieder, et al.
Inflammatory Bowel Diseases|June 30, 2026
Association of preoperative neoplasia and rectal cuff inflammation on initial pouchoscopy with subsequent neoplasia development in inflammatory bowel disease patients with an ileal pouch-anal anastomosis: a case-control studyJoseph Carter Powers, Mark Zemanek, Mili Dave, et al.
Alimentary Pharmacology & Therapeutics|March 14, 2022
Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesionsSalam P Bachour, Ravi S Shah, Ruishen Lyu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 30, 2021
Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's DiseaseSalam P Bachour, Ravi S Shah, Ruishen Lyu, et al.
Journal for Immunotherapy of Cancer|November 14, 2024
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse eventsMalek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based TherapeuticCharles S Berenson, Bret Lashner, Louis Y Korman, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
The American Journal of Gastroenterology|November 4, 2010
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Geert R D'Haens, Remo Panaccione, Peter D R Higgins, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Gastroenterology|January 13, 2010
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitisWilliam J Sandborn, Joshua Korzenik, Bret Lashner, et al.
Gastroenterology|March 8, 2008
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trialJames D Lewis, Gary R Lichtenstein, Julius J Deren, et al.
Journal of Crohn'S & Colitis|June 15, 2022
Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrenceSalam P Bachour, Ravi S Shah, Florian Rieder, et al.
Inflammatory Bowel Diseases|June 30, 2026
Association of preoperative neoplasia and rectal cuff inflammation on initial pouchoscopy with subsequent neoplasia development in inflammatory bowel disease patients with an ileal pouch-anal anastomosis: a case-control studyJoseph Carter Powers, Mark Zemanek, Mili Dave, et al.
Alimentary Pharmacology & Therapeutics|March 14, 2022
Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesionsSalam P Bachour, Ravi S Shah, Ruishen Lyu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 30, 2021
Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's DiseaseSalam P Bachour, Ravi S Shah, Ruishen Lyu, et al.
Journal for Immunotherapy of Cancer|November 14, 2024
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse eventsMalek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based TherapeuticCharles S Berenson, Bret Lashner, Louis Y Korman, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
The American Journal of Gastroenterology|November 4, 2010
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Geert R D'Haens, Remo Panaccione, Peter D R Higgins, et al.
Pageof 6